Giulio Marchesini
Epidemiology · 2001–2021
A researcher in the Science corpus: 14 papers; trusts 2 researchers and is trusted by 5 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 215 citations into it; #713 of 2,148 by trust here, #86 by citations
Whom Giulio Marchesini trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Giulio Marchesini overall
- E. Bugianesi
- Megan H. Bair-Merritt
- V. Ratziu
- S. Bellentani
- Marja-Riitta Taskinen
- Z. Younossi
- N. Chalasani
- Q. Anstee
- Amalia Gastaldelli
Papers from Giulio Marchesini's perspective
Ordered by how strongly the researchers Giulio Marchesini trusts endorse each paper. Same corpus, a different order for every researcher.
- Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes (Seminars in liver disease (Print))
- Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference (Hepatology)
- Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (Hepatology)
- Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. (Journal of Clinical Endocrinology and Metabolism)
- Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (Hepatology)
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (Hepatology)
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Hepatology)
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (New England Journal of Medicine)
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease (Hepatology)
- Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* (Journal of Biological Chemistry)
Their papers
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. (2017) — 646 citations
- Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. (2015) — 658 citations
- A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010) — 1,090 citations
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes (2008) — 676 citations
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) — 3,034 citations
- Insulin resistance: A metabolic pathway to chronic liver disease (2005) — 920 citations
- Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (2005) — 1,331 citations
- A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease (2005) — 689 citations
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (2005) — 612 citations
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (2003) — 2,737 citations
- Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. (2002) — 1,293 citations
- Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. (2001) — 2,611 citations